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African-American women have a long-standing approximately 20% higher breast cancer incidence rate than USA White
women under age 40 while rates among Latinas are lower than those of Whites. The reasons for this are not clear, however
they may be due to ethnic differences in circulating oestradiol and progesterone levels. In a cross-sectional study, we
investigated whether anovulation frequency and circulating serum oestradiol and/or progesterone levels vary among normally
cycling nulliparous African-American (n=60), Latina (n=112) and non-Latina White (n=69) women. Blood and urine specimens
were collected over two menstrual cycles among healthy 17- to 34-year-old women. Frequency of anovulation was greater
among White women (nine out of 63, 14.3%) than African-American women (four out of 56, 7.1%) or Latina women (seven
out of 102, 6.9%), although these differences were not statistically signiﬁcant. African-American women had 9.9% (P=0.26)
higher follicular phase oestradiol concentrations than Latina women and 17.4% (P=0.13) higher levels than White women.
African-American women also had considerably higher levels of luteal phase oestradiol (vs Latinas, +9.4%, P=0.14; vs Whites,
+25.3%, P=0.003) and progesterone (vs Latinas, +15.4%, P=0.07; vs Whites, +36.4%, P=0.002). Latina women were also
observed to have higher follicular oestradiol, and luteal oestradiol and progesterone levels than White women (follicular
oestradiol: +6.8%, P=0.48; luteal oestradiol: +14.6%, P=0.04; luteal progesterone: +18.2%, P=0.06). These results suggest that
exposure to endogenous steroid hormones may be greater for young African-American and Latina women than for Whites.
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African-American women have a long-standing approximately 20%
higher breast cancer incidence rate than USA White women under
age 40, while rates among Latinas are lower than those of Whites
(Gray et al, 1980; Parkin et al, 1997; SEER Program, 2001). The
reasons for this are not clear, however they may be due to ethnic
differences in circulating oestradiol (E2) and progesterone (P4) levels.
Oestradiol is an established breast-cell mitogen, and considerable
epidemiological and experimental evidence indicates that women
with higher circulating levels are at greater risk of developing breast
cancer (Bernstein and Ross, 1993; Pike et al, 1993; Thomas et al,
1997; Hankinson et al, 1998). Considerable evidence also exists indi-
cating that progestins play an important role in breast carcinogenesis.
Recent epidemiological studies have shown that postmenopausal
hormone replacement therapy in the form of estrogen–progestin
replacement therapy (EPRT) increases breast cancer risk to a much
greater extent than estrogen (alone) replacement therapy (ERT;
Magnusson et al, 1999; Ross et al, 2000; Schairer et al, 2000). These
results are supported by the ﬁnding that mammographic densities
are increased much more by EPRT than ERT (Greendale et al,
1999), and so is breast-cell proliferation (Hofseth et al, 1999).
In the present study, we evaluated differences in ovarian func-
tion in African-American, Latina and non-Latina White young
women in Los Angeles who were recruited as part of a cross-
sectional investigation of the frequency of anovulation and of
circulating serum E2 and P4 levels among ‘normally cycling’ nulli-
parous women.
SUBJECTS AND METHODS
We collected blood and urine specimens and questionnaire data
from 241 healthy female college students, who were not athletes.
Most subjects were studied over two menstrual cycles.
Subjects
Study subjects had to meet the following criteria: 18 to 35 years of
age; nulliparous; free of underlying conditions or medication use
(within the previous 6 months) that may interfere with ovulation
and/or hormone levels (speciﬁcally no use of cimetidine, thyroid
supplements, or o-3 fatty acid supplements; no general anaesthe-
sia); no hormonal contraceptive use over the previous 6 months
and no planned use of a hormonal contraceptive over the course
of the two menstrual cycles being studied; and with self-reported
‘regular cycles’. Volunteers were recruited at colleges within the
Los Angeles area: University of Southern California, California
State University at Los Angeles, Santa Monica College, Los Angeles
Community College, Los Angeles Trade Tech, and West Los
Angeles College. Volunteers were sought by posting ﬂiers around
campuses, by placing advertisements in college newspapers, and
by making brief presentations to students attending classes in the
science and health science ﬁelds. Eligible volunteers were asked
to notify us of the ﬁrst day of their next menstrual cycle. At that
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www.bjcancer.comself-administered questionnaire, to receive urine-collection bottles,
and to receive information concerning the conduct of the study
and their scheduled blood-draw appointments. The study protocol
was approved by the Institutional Review Board of the Keck School
of Medicine of the University of Southern California.
Questionnaire data collection
The self-administered questionnaire included basic demographic
questions (age, ethnicity), age at menarche, use of tobacco and
alcohol, and a section on exercise habits.
Our main measure of exercise was the ‘College Alumnae Ques-
tionnaire‘ (CAQ) developed by Paffenbarger et al (1993), which
quantiﬁes exercise by type, intensity and duration. When this ques-
tionnaire is used in conjunction with the ‘Compendium of Physical
Activities – Physical Activity Index’ (CPA–PAI), it allows for the
computation of metabolic activity in MET-minutes, i.e., duration
of activity multiplied by the ratio of the metabolic rate for the
speciﬁc activity divided by the resting metabolic rate (Ainsworth
et al, 1993a). This has been validated in both women and men,
and has been used extensively in studies of the association of exer-
cise activity and heart disease rates, longevity, cardiorespiratory
ﬁtness and energy balance (Ainsworth et al, 1993b). The CPA–
PAI allows for a detailed description of the form and intensity of
most exercise activities. To reduce variation in coding of exercise
activities, one of us (A Afghani) coded all questionnaires.
Sample collection
During the ﬁrst menstrual cycle (‘blood cycle’), subjects were asked
to provide from two to ﬁve blood samples (depending on the
length of the cycle). Counting the ﬁrst day of menstrual bleeding
as cycle day 1, blood was drawn on cycle days 11 (+1) and 22
(+1), and subsequently at weekly intervals on days 29 (+1), 36
(+1) and 42 (+1) until menses occurred. We allowed a +1
day variation in collection date to avoid having to collect samples
on weekends and to allow for unavoidable conﬂicts. Subjects
reported to a local laboratory between 07:00 and 09:30 h in a fast-
ing state and having refrained from exercise that morning prior to
the blood draw. Serum was separated, aliquoted and stored at
7868C at our central laboratory. During a second menstrual cycle
(‘urine cycle’), ﬁrst morning urine samples were collected on cycle
day 10, and subsequently every 4th day until the ﬁrst day of the
next cycle. Participants were asked to place urine samples in their
home refrigerators and to bring urine specimens in a freezer lunch
bag with frozen blue ice (supplied in the kit) to a drop-off refrig-
erator (48C) at their respective colleges for pick-up. Samples were
then catalogued, aliquoted and stored at 7868C at our central
laboratory.
Hormone assays
Serum E2,P 4, and urinary pregnanediol glucuronide (Pdiol-3G)
were measured in the laboratory of Dr Stanczyk. Laboratory
technicians were blinded to the ethnicity and other details of
study subjects. Serum E2 was measured following extraction with
ethyl acetate:hexane, using an iodinated radioimmunoassay
(RIA) kit from Pantex (Santa Monica, California, USA) as
described previously (Stanczyk et al, 1988). The intra-assay coef-
ﬁcient of variation (CV) is 10.9% and the inter-assay CV is
9.1%. Serum P4 was measured by RIA after extraction with
hexane as described previously (Scott et al, 1978). The intra-assay
CV is 6.2% and the inter-assay CV is 8.7%. Urinary Pdiol-3G
was measured by direct RIA as described previously (Stanczyk
et al, 1980). The intra-assay CV is 3.1% and the inter-assay
CV is 10.9%. Urinary Pdiol-3G concentrations are expressed
per urinary concentration of creatinine, which was measured
colourimetrically.
Determination of ovulation
We classiﬁed each blood cycle as ovulatory, anovulatory or indeter-
minate based on the availability (and value) of a serum P4 on days
73t o711 (i.e., the availability of a serum P4 between 3 and 11
days before the onset of the next menses). A serum P4
43.0 ng ml
71 was considered as indicative of ovulation and only
ovulatory cycles were used in the analyses of serum hormone levels.
For these analyses, the luteal phase sample that was closest to the
onset of the next menses within the 73t o711 range was used
for analyses of luteal phase E2 and P4 levels.
We classiﬁed each urine cycle as ovulatory, anovulatory or inde-
terminate based on the availability (and value) of urinary Pdiol-3G
on days 73t o711 (i.e., the availability of a Pdiol-3G between 3
and 11 days before the onset of the next menses); only one value
per subject during the luteal phase was used (the one closest to
the onset of the next menses within the acceptable range). A
Pdiol-3G level 41.25 mgm g
71 was considered indicative of ovula-
tion (see Discussion).
Statistical methods
Logistic regression models were used for the analysis of anovula-
tion frequency, with adjustment for BMI (body-mass index;
quartiles), exercise (MET-mins/day; tertiles), smoking (never, past,
current), alcohol (never, past, current), age at menarche (411, 12,
13, 14+ years), gynaecologic age (current age – age at menarche;
48, 8+ years), cycle length (426, 27–28, 29–30, 31–32, 33+
days) and days to start of next menstrual cycle (3–5, 6–8, 9–
11 days). Geometric mean serum E2 and P4 values were compared
across the three ethnic groups using multiple regression methods,
with adjustment for the variables described above for the luteal
phase analysis; and for the follicular phase (day 11) E2 analysis
adjustment was made for the variables described above but the
days to start of next menstrual cycle groups were changed to
417, 18–19, 20–21, and 22+ days.
RESULTS
Two hundred and forty-one eligible women between the ages of 17
and 34 provided specimens for the study; of these 60 were African
Americans, 112 were Latinas (Mexicans or other Central American
Hispanics) and 69 were non-Latina Whites (herein referred to as
Whites). Ovulatory status during the blood cycle could be deter-
mined for 221 of the 241 women, i.e., we had a P4 value for 221
of the 241 women in the 73t o711 day range. During the urine
cycle, we restricted the analysis to women whose ovulatory status
could be determined during the blood cycle; ovulatory status was
determined for 152 women.
Descriptive characteristics by ethnic group are presented in
Table 1. The White women began menstruating at a later age than
African-American and the Latina women (P=0.038). The White
women also spent more time exercising (P=0.001) and were more
likely to be a current drinker of alcohol or a smoker than the Afri-
can-American or Latina women. The mean BMI for African-
Americans and Latinas was signiﬁcantly greater than that of Whites
(P=0.032). Gynaecologic age and cycle lengths were similar in the
different ethnic groups.
The proportion of women classiﬁed as anovular differed by
ethnic group (Table 2), however, the differences were not statisti-
cally signiﬁcant. During the blood cycle, 7.1% of the African-
American, 6.9% of the Latina and 14.3% of the White women were
classiﬁed as anovular. A similar racial/ethnic pattern was observed
after adjustment for possible predictors of ovulation status (see
Statistical methods section; data not shown). A similar pattern
was also seen during the urine cycle (Table 2).
The African-American and Latina women categorized as anovu-
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groups. The BMIs of the anovular African-American women
(n=4; 16.9, 33.4, 40.8 and 49.8 kg m
72) were on the extremes of
the BMI distribution for African-Americans in this study. The
BMIs for the anovular Whites were between 20.5 and
25.2 kg m
72. The greater frequency of anovulation of the White
women remained when the analysis was restricted to women with
BMIs within the ‘normal healthy’ range (18.5–24.9 kg m
72) and
who exercised in the moderate range (43000 MET-minutes per
week; Table 2); in this subgroup of women, none of the African-
American, 8.3% of the Latina and 15.6% of the White women were
anovular.
Geometric mean follicular serum E2 and luteal phase serum E2
and P4 levels among the ovulating women are shown in Table 3.
In adjusted analyses, the African-Americans had 9.9% (P=0.26)
higher levels of follicular E2 than the Latina women and 17.4%
(P=0.13) higher levels than the White women. The African-Amer-













Table 1 Descriptive characteristics by ethnic group
a
African-Americans Latinas Whites
Characteristics (n=56) (n=102) (n=63)
Age (years) 22.1+3.9 21.3+2.8 22.8+4.4
Weight (kg) 65.4+16.6 61.8+12.3 62.3+12.1
Height (m) 1.65+0.073 1.60+0.069 1.67+0.076
BMI (kg m
72) 24.1+5.9 24.2+4.9 22.2+3.8
Exercise (MET-minutes per week) 809.0+1174.2 747.1+1132.1 1442.2+1381.2
Age of menarche (years)
b 12.7+1.7 12.7+1.4 13.2+0.9
Alcohol use current, n (%) 4 (7.1%) 12 (11.8%) 26 (41.3%)
Smoking current, n (%) 1 (1.8%) 7 (6.9%) 11 (17.5%)
Gynaecological age
c 9.9+3.8 9.1+2.9 10.1+4.4
Cycle length (days)
Blood cycle 29.1+4.2 29.9+3.9 29.0+3.0
Urine cycle 29.4+4.9 28.6+4.5 28.8+3.4
aValues given are mean (standard deviation), or number (%).
bAge at menarche as reported in years+0.5.
cGynaecological
age=current age7age at menarche.
Table 2 Anovulation frequency in the blood cycle and in the urine cycle by ethnic group
Number not ovulating/N
a
Women with 18.54BMI424.5 and
Cycle Ethnicity All women (%) 43000 MET-minutes per week (%)
Blood cycle African-American 4/56 (7.1) 0/34 (0.0)
Latina 7/102 (6.9) 5/60 (8.3)
White 9/63 (14.3) 7/45 (15.6)
Urine cycle African-American 3/43 (7.0) 0/28 (0.0)
Latina 7/66 (10.6) 4/42 (9.5)
White 7/43 (16.3) 5/32 (15.6)
aN= number of women in category with known serum P4 value between 3 and 11 days before the ﬁrst day of
the next menstrual cycle.
Table 3 Geometric mean serum E2 and P4 concentrations
a
Variable African-Americans Latinas Whites
All women n=52
b n=91 n=54




E2, luteal 227.3 207.8 181.4
(pg ml
71) (5.426+0.071) (5.337+0.057) (5.201+0.065)
P4, luteal 15.0 13.0 11.0
(ng ml
71) (2.706+0.091) (2.564+0.074) (2.397+0.084)
Women: 18.54BMI425 kg m
72
and 43000 MET-minutes per week n=34 n=55 n=38
E2, follicular 144.2 132.7 112.9
(pg ml
71) (4.971+0.153) (4.888+0.124) (4.726+0.130)
E2, luteal 225.1 225.9 180.5
(pg ml
71) (5.417+0.102) (5.420+0.083) (5.196+0.087)
P4, luteal 15.5 14.6 11.9
(ng ml
71) (2.741+0.128) (2.681+0.105) (2.478+0.109)
aAdjusted values (see Materials and Methods).
bn= number of ovulating women; numbers vary slightly due to missing data;
cMean natural logs+associated standard errors are shown in parentheses below the geometric mean.
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P4 (vs Latinas, +15.4%, P=0.07; vs Whites, +36.4%, P=0.002). Folli-
cular E2, and luteal E2 and P4 levels were higher for Latinas than
Whites (follicular E2: +6.8%, P=0.48; luteal E2: +14.6%, P=0.04;
luteal P4: +18.2%, P=0.06). The racial/ethnic differences in serum
hormone levels were also observed among women with BMIs with-
in the normal weight range (18.5–24.9 kg m
72) who exercised in
the moderate range (43000 MET-minutes per week; Table 3).
DISCUSSION
Little is known regarding ethnic differences in ovarian function.
Using National USA Survey data, MacMahon (1973) ﬁrst described
African-Americans as having an earlier age at menarche than
Whites and this was also found in a recent study conducted among
a cohort of schoolgirls in Los Angeles (Koprowski et al, 1999).
Koprowski et al (1999) also found the White girls to have a later
age at menarche than Latina girls, but there was no difference
between the African-Americans and the Latinas. The White women
in our study also began menstruating at a signiﬁcantly later age.
We now provide evidence that White women have a greater
frequency of anovular menstrual cycles than African-American
and Latina women. Although anovulation among African-Ameri-
can women could be explained by extremes in BMI, and Whites
exercised more than African-Americans and Latinas, extremes in
BMI or greater exercise among Whites could not account for the
observed racial/ethnic differences in anovulation frequency. When
limiting the analysis to women who did not exercise vigorously
(43000 MET-minutes per week) and had BMIs within the
‘normal-healthy’ range (18.5–24.9 kg m
72), Whites were still
observed to have a greater frequency of anovular menstrual cycles
than African-Americans.
The ethnic differences in anovulation frequency that we
observed during the blood cycle remained when the acceptable
window of days to the onset of next menses was further restricted
from 74t o711 or 75t o710, and also when the P4 level cut-
point used to deﬁne an ovulatory cycle was increased to 4.0 or
5.0 ng ml
71. The 73t o711 range of informative days was based
on the results presented by Israel et al (1972) and inspection of our
results when we had multiple P4 values for participants. Israel et al
(1972) suggest that to deﬁne whether ovulation has occurred on
the basis of a P4 value, the specimen should be drawn from 4 to
11 days before the onset of the next menses rather than from 3
to 11 days; however, we found no inconsistencies when we used
the slightly wider time frame. During the urine cycle, a Pdiol-3G
to creatinine ratio greater than 1.25 mgm g
71 was initially selected
to deﬁne ovulatory status because this cut-point produced a
comparable overall frequency (i.e., over all groups combined) of
anovulation to that observed in the blood cycle. As with the serum
determination of ovulation, the between ethnic group comparisons
were not sensitive to the speciﬁed permissible window, but they
were to the Pdiol-3G/creatinine cut-point. Ethnic differences were
no longer apparent when a Pdiol-3G value 41.75 ng mg
71 creati-
nine was used to deﬁne ovulatory status; at this cut-point
approximately 20% of each ethnic group were classiﬁed as anovu-
lar. This high percentage is not compatible with the results from
the serum P4 level determination, and we believe the results at
the 1.25 mgm g
71 cut-point more likely represent the true anovu-
lation incidence. However, the literature on the ‘correct’ cut-point
is sparse, and before future studies use Pdiol-3G to determine
ovulatory status, studies need to be performed to establish whether
the critical Pdiol-3G/creatinine level is uniform across ethnic
groups, as we have assumed here.
Differences in premenopausal steroid hormone levels between
African-American and White women have been reported
previously, however, data are limited and comparisons with Latinas
have not been investigated. In a diet-intervention study, Woods et
al (1996) observed at baseline that African-American women
(n=21) had a 55% higher follicular-phase E2 level than Whites
(n=68; P40.001). In a study of pregnant women, Henderson et
al (1998) also observed African-American women to have higher
steroid hormone levels than White women during the ﬁrst trime-
ster of pregnancy. Our results support these ﬁndings, as we
observed African-American women to have higher levels of both
follicular E2 and luteal E2 and P4 than Latina and White women.
Our data suggest that the higher breast cancer incidence of Afri-
can-American women under 40 years of age may be due in part to
ethnic differences in ovarian function; we observed African-Amer-
ican women to have an earlier age at menarche, a greater frequency
of ovular cycles, and, among ovulating women, higher circulating
levels of E2 and P4. We also provide evidence that Latina women
have an earlier age at menarche and higher luteal E2 and P4
hormone levels than White women. The Latina women in this
study were identiﬁed from colleges in the Los Angeles area and
do not include Latinas of low SES. Although overall breast cancer
rates in young Latina women in Los Angeles are some 25% lower
than the rates in Whites, the rates in middle class Latinas are only
12% lower than in Whites (unpublished data from the Los Angeles
County Cancer Surveillance Program, part of the SEER network of
registries). Based on these ﬁndings, one may predict that breast
cancer rates among young Latina women may soon rise to at least
the high breast cancer rates observed in White women.
In summary, this paper supports the work of others in demon-
strating ethnic differences in ovarian function and further adds to
the sparse data available in the Latina population. In order to gain
a more comprehensive and thorough understanding of the
complexities and nuances associated with this extremely dynamic
system, daily measurements of gonadotropins and steroid
hormones collected over multiple menstrual cycles among a large
sample of women are needed. Inter-individual and inter-ethnic
differences in ovarian function are most likely due to the collective
effects of nutrition, energy expenditure, caloric intake, body size
and genetic variation. In addition to monitoring physical activity,
future studies will also need to collect comprehensive dietary
records to examine the relationship between energy balance and
ovulatory function. Research efforts should also be aimed at iden-
tifying the relevant genes involved in regulating gonadotropin and
steroid hormone production, and investigating whether functional
polymorphisms in these genes lead to variation in ovarian function.
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